Paclitaxel trevatide

Drug Profile

Paclitaxel trevatide

Alternative Names: ANG-1005; AngioPep1; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Glioma

Most Recent Events

  • 08 Dec 2016 Paclitaxel trevatide is still in phase II trials for Glioblastoma in USA (IV)
  • 07 Oct 2016 Efficacy data from a phase II trial in Brain metastases (from breast cancer) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 27 Apr 2016 Angiochem initiates an expanded-access programme for Anaplastic astrocytoma and Anaplastic oligodendroglioma (Recurrent, Late-stage disease) in USA (IV) before April 2016 (NCT02755987)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top